Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection.
An HIV vaccine capable of providing sterilizing immunity from vaginal infection would reduce the spread of HIV to women. Unfortunately, only one of the four HIV-1 vaccine clinical trials has demonstrated any level of protection (31%) against HIV-1 transmission. Additionally, only one topical microbicide clinical trial has reported an overall reduction in HIV transmission (39%). Developing even more effective vaccines and microbicides will require a better understanding of the key events involved in HIV infection and dissemination at the site of exposure. Novel immunodeficient mice capable of being systemically reconstituted with human hematopoietic stem cells have provided new systems where HIV transmission studies can be performed. Specifically, a humanized mouse model of vaginal HIV transmission has been developed that utilizes the humanized bone marrow-liver-thymus (BLT) mouse. The female reproductive tract (FRT) of humanized BLT mice is reconstituted with functional human immune cells rendering them susceptible to vaginal HIV-1 infection. In this review we focus on four aspects of BLT mice for the study of vaginal HIV-1 transmission: (1) we discuss methods for creating humanized BLT mice and their reconstitution with human hematopoietic cells, (2) we describe reconstitution of the BLT mouse FRT with human immune cells, (3) we highlight the work done regarding vaginal HIV-1 transmission and (4) we summarize the efficacy of systemic pre-exposure prophylaxis (PrEP) to prevent vaginal HIV-1 transmission in BLT mice. BLT mice are a highly relevant small animal model for studying vaginal HIV-1 transmission, prevention and therapy.
Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7042, USA.
Rikke
R
Olesen
Angela
A
Wahl
Paul W
PW
Denton
J Victor
JV
Garcia
D016915:AIDS Vaccines; D000818:Animals; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D005260:Female; D015658:HIV Infections / Q000276:immunology* / Q000628:therapy / Q000635:transmission; D015497:HIV-1 / Q000276:immunology* / Q000472:pathogenicity; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017053:Infection Control; D051379:Mice; D008815:Mice, Inbred Strains; D011247:Pregnancy; D014621:Vagina / Q000276:immunology* / Q000378:metabolism / Q000821:virology
D016915:AIDS Vaccines
J Virol. 2002 Oct;76(19):9868-76
12208964
J Exp Med. 2007 Apr 16;204(4):705-14
17389241
J Virol. 2007 Jan;81(1):395-405
17050597
Immunology. 1999 Feb;96(2):272-7
10233705
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5640-5
15064398
PLoS One. 2010 Jan 21;5(1):e8829
20098623
Curr HIV/AIDS Rep. 2009 Feb;6(1):13-9
19149992
J Leukoc Biol. 1997 Apr;61(4):427-35
9103229
J R Soc Med. 1992 Nov;85(11):706-7
1474562
Science. 2010 Sep 3;329(5996):1168-74
20643915
J Exp Med. 2004 Sep 20;200(6):761-70
15365095
Lancet Infect Dis. 2008 Sep;8(9):553-63
18684670
Am J Pathol. 1991 Jul;139(1):149-60
1853930
Immunity. 2007 Feb;26(2):257-70
17306567
Biol Reprod. 2005 Dec;73(6):1253-63
16093359
J Infect Dis. 2005 May 1;191(9):1403-9
15809897
Am J Pathol. 1987 Apr;127(1):66-73
3565538
Science. 2003 May 23;300(5623):1295-7
12730499
Stem Cells. 1998;16(3):166-77
9617892
PLoS Med. 2008 Jan 15;5(1):e16
18198941
Antiviral Res. 2007 Jul;75(1):1-13
17116336
J Virol. 1997 May;71(5):3498-506
9094621
J Reprod Med. 1984 Apr;29(4):269-71
6716372
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11504-9
16061810
AIDS. 2010 Mar 13;24(5):621-35
20179575
J Virol. 2005 Jul;79(14):9217-27
15994816
J Virol. 2000 Jun;74(12):5577-86
10823865
Science. 1999 Nov 12;286(5443):1353-7
10558989
J Immunol. 2005 May 15;174(10):6477-89
15879151
J Exp Med. 2009 May 11;206(5):1117-34
19414559
Curr Opin HIV AIDS. 2008 Sep;3(5):567-73
19373023
Antiviral Res. 2010 Jan;85(1):159-75
19622373
Mucosal Immunol. 2010 May;3(3):280-90
20147895
J Med Primatol. 1992 Feb-May;21(2-3):64-8
1433268
J Exp Med. 2004 Sep 20;200(6):749-59
15365096
PLoS Pathog. 2010 Apr 08;6(4):e1000852
20386714
Hum Immunol. 2010 Jun;71(6):551-9
20298731
PLoS One. 2010 Feb 19;5(2):e9310
20174579
J Infect Dis. 1991 Oct;164(4):769-72
1680138
Cell. 2000 Mar 3;100(5):587-97
10721995
PLoS Med. 2006 Nov;3(11):e454
17090213
J Infect Dis. 2009 Sep 15;200(6):965-72
19671015
J Exp Med. 2004 Nov 15;200(10):1279-88
15545354
AIDS. 1994 Sep;8(9):1325-9
7802988
Med Microbiol Immunol. 2005 Aug;194(4):201-6
15843997
Nat Med. 2006 Nov;12(11):1316-22
17057712
J Infect Dis. 1999 May;179 Suppl 3:S413-7
10099109
Am J Reprod Immunol. 1997 Nov;38(5):350-9
9352027
Blood. 2006 Jul 15;108(2):487-92
16410443
Anat Rec. 1964 Sep;150:51-65
14218417
J Virol. 2000 Jan;74(1):57-64
10590091
Nature. 2009 Apr 23;458(7241):1034-8
19262509
Clin Exp Immunol. 1992 Dec;90(3):530-8
1360881
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12381-6
20616092
Nature. 2010 Mar 11;464(7286):217-23
20220840
Science. 1999 Apr 30;284(5415):816-9
10221916
Trends Pharmacol Sci. 2010 Feb;31(2):74-81
19963288
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
18490657
Lancet. 2001 Apr 14;357(9263):1149-53
11323041
J Virol. 2009 Jul;83(14):7305-21
19420076
N Engl J Med. 2000 Mar 30;342(13):921-9
10738050